Paiella Salvatore, De Pastena Matteo, Pollini Tommaso, Zancan Giovanni, Ciprani Debora, De Marchi Giulia, Landoni Luca, Esposito Alessandro, Casetti Luca, Malleo Giuseppe, Marchegiani Giovanni, Tuveri Massimiliano, Marrano Enrico, Maggino Laura, Secchettin Erica, Bonamini Deborah, Bassi Claudio, Salvia Roberto
Salvatore Paiella, Matteo De Pastena, Tommaso Pollini, Giovanni Zancan, Debora Ciprani, Luca Landoni, Alessandro Esposito, Luca Casetti, Giuseppe Malleo, Giovanni Marchegiani, Massimiliano Tuveri, Enrico Marrano, Laura Maggino, Erica Secchettin, Deborah Bonamini, Claudio Bassi, Roberto Salvia, General and Pancreatic Surgery Department, Pancreas Institute, University and Hospital Trust of Verona, 37134 Verona, Italy.
World J Gastroenterol. 2017 May 7;23(17):3077-3083. doi: 10.3748/wjg.v23.i17.3077.
To compare surgical and oncological outcomes after pancreaticoduodenectomy (PD) in patients ≥ 75 years of age with two younger cohorts of patients.
The prospectively maintained Institutional database of pancreatic resection was queried for patients aged ≥ 75 years (late elderly, LE) submitted to PD for any disease from January 2010 to June 2015. We compared clinical, demographic and pathological features and survival outcomes of LE patients with 2 exact matched cohorts of younger patients [≥ 40 to 64 years of age (adults, A) and ≥ 65 to 74 years of age (young elderly, YE)] submitted to PD, according to selected variables.
The final LE population, as well as the control groups, were made of 96 subjects. Up to 71% of patients was operated on for a periampullary malignancy and pancreatic cancer (PDAC) accounted for 79% of them. Intraoperative data (estimated blood loss and duration of surgery) did not differ among the groups. The overall complication rate was 65.6%, 61.5% and 58.3% for LE, YE and A patients, respectively, = NS). Reoperation and cardiovascular complications were significantly more frequent in LE than in YE and A groups ( = 0.003 and = 0.019, respectively). When considering either all malignancies and PDAC only, the three groups did not differ in survival. Considering all benign diseases, the estimated mean survival was 58 and 78 mo for ≥ and < 75 years of age (YE + A groups), respectively ( = 0.012).
Age is not a contraindication for PD. A careful selection of LE patients allows to obtain good surgical and oncological results.
比较75岁及以上患者行胰十二指肠切除术(PD)后的手术及肿瘤学结局与两个较年轻患者队列的情况。
查询2010年1月至2015年6月期间因任何疾病接受PD的75岁及以上患者(老年晚期,LE)的前瞻性维护的机构胰腺切除数据库。根据选定变量,我们比较了LE患者与2个年龄匹配的较年轻患者队列[40至64岁(成年人,A)和65至74岁(年轻老年人,YE)]行PD后的临床、人口统计学和病理特征及生存结局。
最终的LE人群以及对照组均由96名受试者组成。高达71%的患者因壶腹周围恶性肿瘤接受手术,其中胰腺癌(PDAC)占79%。各组间术中数据(估计失血量和手术持续时间)无差异。LE、YE和A组患者的总体并发症发生率分别为65.6%、61.5%和58.3%(P = 无统计学意义)。LE组再次手术和心血管并发症的发生率明显高于YE组和A组(分别为P = 0.003和P = 0.019)。当考虑所有恶性肿瘤及仅PDAC时,三组的生存率无差异。考虑所有良性疾病时,75岁及以上(YE + A组)和75岁以下患者的估计平均生存期分别为$58$个月和$78$个月(P = 0.012)。
年龄并非PD的禁忌证。仔细挑选LE患者可获得良好的手术及肿瘤学结果。